Rare gene fusions found across dozens of cancer types; the first target where a drug was approved for any tumour carrying it. This dossier gathers the 3 products (3 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
NTRK1/2/3 encode the neurotrophin receptor kinases TrkA, TrkB and TrkC.
- Infantile fibrosarcoma
- Secretory breast/salivary carcinoma
- Thyroid, colorectal, lung (rare)
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Sarcomas | >90% | Infantile fibrosarcoma (ETV6-NTRK3) | <1% in adult common cancers | Wikipedia |
| Thyroid cancer | 2-3% | Fusion | Wikipedia | |
| Colorectal cancer | <1% | Fusion | Enriched in MSI-high | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Mutation hotspots and which drugs address them
| Residue | Kind | How common | What it does | Addressed by | Defeats | Source |
|---|---|---|---|---|---|---|
| G595R (solvent front) 595 | Resistance | not sourced | The main acquired escape from larotrectinib and entrectinib; repotrectinib covers it. | Drilon et al., Cancer Discov 2017 | ||
| G667C (xDFG) and F589L (gatekeeper) 667 | Resistance | not sourced | Further on-target escapes with partial coverage by next-generation TRK inhibitors. | Drilon et al., Cancer Discov 2017 |
Frequencies are quoted from the source on each row; a blank means no figure was sourced, not that it is rare. Domain boundaries are approximate. Sources for the map: COSMIC: NTRK1.
Products by modality and phase
Browse products →| Modality | Approved |
|---|---|
| Small molecule 2 | |
| Small-molecule TRK/ROS1/ALK TKI 1 |
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes that involve this target
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways where it is a node
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics and assays
Assay registry →| Assay | Platform | Cut-off | Gates |
|---|---|---|---|
| FoundationOne CDx Foundation Medicine (Roche) · FDA CDx 2017 | NGS tissue | Per companion claim: EGFR, ALK, BRAF V600, ERBB2 amplification, KRAS wild-type, BRCA1/2 and HRR genes, PIK3CA, MET exon 14, RET, FGFR2 fusions, IDH1, NTRK fusions; MSI-high; TMB at least 10 mutations per megabase | |
| FoundationOne Liquid CDx Foundation Medicine (Roche) · FDA CDx 2020 | NGS plasma | Per companion claim: EGFR (osimertinib, erlotinib, gefitinib), ALK (alectinib), BRCA1/2 and ATM (olaparib, rucaparib), PIK3CA (alpelisib), FGFR3 (erdafitinib), NTRK and RET; negative plasma results reflex to tissue |
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Key papers and the live literature
Preprints →Query for this target: (TITLE:"NTRK" OR ABSTRACT:"NTRK" OR TITLE:"NTRK1" OR ABSTRACT:"NTRK1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NTRK, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ntrk.json. Licence CC BY 4.0.